Monopar Therapeutics Inc. (MNPR)
MNPR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1645469/000143774926010025/0001437749-26-010025-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | MNPR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2019 |
| SEC CIK | 0001645469 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$13.7M |
| Operating income | -$16.7M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $61.8M |
| Total assets | $140.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "In October 2026, the Company analyzed its cash requirements through March 31, 2028, and has determined that, based upon the Company's current available cash and cash equivalents and investments, the Company has no substantial doubt about its ability to continue as a going concern." | 10-Q 2026-11-12 |
| Cash and burn | $52.6M cash; operating cash flow -$4.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 6,776,773 (2026-10-31); 6,682,584 a year earlier; 14,866,400 three years earlier. 3y figure adjusted for split (1-for-5 overall). | Cover page 2026-10-31 |
| Reverse splits, 3 years | 1; latest 1-for-5 on 2024-08-13 | Source 2024-08-13 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | BPM LLP, Santa Rosa, California, United States | PCAOB Form AP 2026-04-03 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $105K, sold $3.8M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $0 | -$6.2M | -$6.2M | $52.6M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $0 | -$5.3M | -$3.2M | $52.8M | No debt tags | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | $0 | -$3.9M | -$3.5M | $52.5M | No debt tags | Needs four quarters | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | Not filed | -$5.2M | -$3.1M | $61.8M | No debt tags | $0 | 10-K 2026-03-27 |
| Q3 2025 2025-09-30 | Not filed | -$3.4M | -$2.4M | $127.7M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$2.5M | -$1.1M | $39.5M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2025 2025-03-31 | Not filed | -$2.6M | -$5.7M | $39.7M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2024 2024-12-31 | Not filed | -$10.9M | -$2.0M | $45.8M | No debt tags | $0 | 10-K 2026-03-27 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM 424B5 | 424B5 | 2025-09-24 |
| Latest annual report FORM 10-K/A | 10-K/A | 2026-04-01 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-12 |
| Latest current report FORM 8-K | 8-K | 2026-11-12 |
| Latest proxy FORM DEFA14A | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 539 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.8% |
| 1 month | -0.1% |
| 3 months | -34.8% |
| Year to date | +10.3% |
| 1 year | -17.3% |
| From 52-week high | -41.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CAPR | Capricor Therapeutics Inc. | $8.30 | -12.91% | $482.6M |
| NGNE | Neurogene Inc. Common Stock | $23.30 | -2.63% | $482.3M |
| PHAT | Phathom Pharmaceuticals Inc. | $5.88 | -2.97% | $478.0M |
| STTK | Shattuck Labs Inc. | $4.66 | +0.21% | $474.6M |
| AQST | Aquestive Therapeutics Inc. | $3.76 | -3.84% | $472.6M |
| OCS | Oculis Holding AG | $7.63 | -0.13% | $469.9M |
| GYRE | Gyre Therapeutics Inc. | $4.39 | +1.86% | $506.3M |
| LYEL | Lyell Immunopharma Inc. | $14.65 | +2.45% | $469.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier